Calbeta5 mg+50 mg

Calbeta 5 mg+50 mg is a fixed-dose combination antihypertensive that pairs a calcium channel blocker with a cardioselective beta-blocker. By acting through two complementary mechanisms, it provides more effective blood pressure and cardiac workload control than either drug alone. It is commonly prescribed for:

• Essential hypertension — for patients who need more than single-agent therapy to reach target blood pressure
• Angina pectoris with coexisting hypertension — where chest pain and elevated blood pressure occur together
• Post-myocardial infarction (post-MI) management — to help reduce cardiac workload and recurrence risk after a heart attack
• Refractory angina pectoris — in patients whose chest pain has not responded adequately to nitrate therapy

This combination is typically prescribed after a physician has assessed that dual-mechanism therapy is appropriate, rather than as a first-line, standalone option for newly diagnosed hypertension. It should always be taken under medical supervision and as prescribed by a registered physician.

Combined antihypertensive preparations

This combination brings together two antihypertensive agents with distinct and complementary mechanisms of action.

Amlodipine

Amlodipine is a long-acting dihydropyridine calcium channel blocker. It inhibits the transmembrane influx of calcium ions into vascular smooth muscle and, to a lesser extent, cardiac muscle. Because its effect is more pronounced on vascular smooth muscle than on the heart, Amlodipine acts primarily as a peripheral vasodilator — relaxing arterial walls, lowering peripheral vascular resistance, and reducing blood pressure. It also reduces coronary vasoreactivity and lowers cardiac oxygen demand by decreasing afterload, which contributes to its anti-anginal effect. Its long half-life allows for smooth, once-daily dosing with a gradual onset of action.

Atenolol

Atenolol is a cardioselective (beta-1 selective) beta-blocker; its cardioselectivity is dose-dependent, meaning selectivity may diminish at higher doses. It lowers blood pressure primarily by reducing cardiac output, decreasing plasma renin activity, and blunting sympathetic outflow from the central nervous system. Atenolol's negative inotropic and negative chronotropic effects — reducing the force and rate of heart contraction — also lower myocardial oxygen demand, which is central to its anti-anginal and cardioprotective benefit.

Combined Effect

Together, Amlodipine's vasodilatory action and Atenolol's cardiac rate- and output-lowering action produce a synergistic reduction in blood pressure and cardiac workload, making the combination particularly useful when hypertension and angina coexist.

Dosage must always be individualized by a registered physician based on the patient's blood pressure response, tolerability, and overall clinical condition.

• Usual starting dose: One tablet of Amlodipine 5 mg + Atenolol 25 mg (5/25 mg), taken orally once daily.
• Dose escalation: If blood pressure or symptom control is inadequate, the physician may increase the dose to two tablets of 5/25 mg daily, or switch to a higher-strength 5/50 mg formulation, depending on response.
• Administration: The tablet can be taken with or without food, ideally at the same time each day to maintain consistent blood levels. It should be swallowed whole with water and not crushed or chewed unless directed otherwise.
• Missed dose: If a dose is missed, it should be taken as soon as remembered unless it is close to the next scheduled dose — in that case, the missed dose should be skipped rather than doubled.

Patients should never adjust the dose or stop the medication on their own, as abrupt discontinuation of the beta-blocker component can be harmful. Always follow the dosage prescribed by a registered physician.

Calbeta 5 mg+50 mg is generally well tolerated, and most side effects are mild and transient. Commonly reported side effects include:

• Fatigue and tiredness
• Headache
• Peripheral edema (mild swelling, typically in the ankles or feet)
• Nausea
• Drowsiness
• Anxiety
• Depression or low mood

Less commonly, patients may experience dizziness, flushing, cold extremities (related to the beta-blocker component), or a slower-than-normal heart rate. Side effects are usually dose-related and tend to diminish as the body adjusts to therapy. Patients should seek prompt medical attention if they experience signs of a severe allergic reaction, fainting, very slow heart rate, or worsening shortness of breath.

Pregnancy: Calbeta 5 mg+50 mg should be used during pregnancy only if the expected benefit to the mother clearly outweighs the potential risk to the fetus. Beta-blockers such as Atenolol have been associated with fetal growth restriction and neonatal bradycardia when used in pregnancy, so alternative antihypertensives are often preferred where possible. Use should only occur under close physician supervision.

Lactation: This combination should not be used by nursing mothers, as both components pass into breast milk. If treatment with this medicine is considered medically necessary, breastfeeding should be discontinued during the course of therapy.

• Bronchospasm / airway obstruction: Use with caution in patients with a history of asthma or airway obstruction, since beta-blockade can trigger or worsen bronchospasm.
• Renal impairment: Generally safe in renal impairment, but caution is required when creatinine clearance falls below 30 mL/min, as excretion of unchanged Atenolol may be reduced, raising the risk of drug accumulation.
• Hepatic impairment: Caution is advised in patients with severe liver disease, since Amlodipine's elimination half-life is prolonged in hepatic impairment, potentially increasing systemic exposure.
• Abrupt discontinuation: This medicine should never be stopped suddenly. Because underlying coronary heart disease may be unrecognized, abrupt withdrawal of beta-blocker therapy can precipitate angina or cardiac events. Any discontinuation should be gradual and supervised by a physician.
• Diabetes: May mask signs of hypoglycemia, such as rapid heartbeat; blood glucose should be monitored closely in diabetic patients.
• Driving and operating machinery: May cause dizziness or fatigue, particularly when starting treatment; patients should assess their response before driving or using machinery.

Overdose with Calbeta 5 mg+50 mg is not well documented, but based on the known effects of its components, overdose may result in pronounced hypotension (low blood pressure) and, less frequently, congestive cardiac failure. Excessive beta-blockade may also cause severe bradycardia, heart block, or bronchospasm.

Management is primarily supportive:

• Unabsorbed drug may be removed via gastric lavage or administration of activated charcoal if the overdose is recent
• Close monitoring of heart rate, blood pressure, and cardiac rhythm
• Symptomatic and supportive treatment, including intravenous fluids, vasopressors, or atropine for symptomatic bradycardia, as clinically indicated

Suspected overdose is a medical emergency and requires immediate hospital evaluation.

• Store below 30°C, in a cool and dry place
• Protect from direct light and moisture
• Keep out of reach of children
• Do not use beyond the expiry date printed on the packaging

• Elderly patients: May be more sensitive to the blood-pressure-lowering effects; a lower starting dose with careful monitoring is often appropriate.
• Children: Safety and efficacy in pediatric patients have not been established; this combination is not recommended for use in children.
• Renal impairment: Dose adjustment or closer monitoring may be needed, particularly when creatinine clearance is below 30 mL/min.
• Hepatic impairment: Caution is required in patients with severe liver disease due to prolonged Amlodipine clearance.
• Diabetic patients: Requires careful blood glucose monitoring, as the beta-blocker component can mask typical hypoglycemia warning signs.